ALBO News and Press, Albireo Pharma Inc. From 01/02/23

Summary ALBO has one approved indication and one more filed for a label expansion. The company has begun a slow revenue stream and has decent cash. A small opportunity presents itself in the company's measured but steady growth. For further details see: Alb...

- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy of Bylvay (odevixibat) in pruritus, bile acids and sleep with a low drug-related diarrhea rate - Data submitted to support use across wide...

– Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise – Dr. Paul Streck, former Chief Medical Officer at Arena Pharmaceuticals, brings significant global drug develop...

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 1...

Albireo Pharma, Inc. (ALBO) Q3 2022 Results Conference Call November 08, 2022 04:30 PM ET Company Participants Hans Vitzthum - Managing Director, LifeSci Advisors Ron Cooper - President and Chief Executive Officer Jan Musin - Chief Scientific Officer, Head of R&a...

Albireo Pharma press release ( NASDAQ: ALBO ): Q3 GAAP EPS of -$1.92 misses by $0.04 . Revenue of $9.83M (+168.6% Y/Y) beats by $0.29M . The Company had cash, cash equivalents and restricted cash of $272.5 million as of September 30, 2022, versus $181.0 million...

Bylvay ® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 million New disease modification and native liver survival data with Bylvay in PFIC patients presented at AASLD Positive Bylvay Phase 3 ASSERT topline data in ALGS p...

Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modification Long-term preservation of native liver in PFIC, improvements in pruritus, bile acids, and increased growth over time Late-breaking oral presentation demonstrates re...

— Eight projects selected for inaugural year of the program — Projects provide solutions to make a tangible difference in the lives of PFIC patients BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company ...

– BOLD is the first, largest, and only global Phase 3 trial designed to meet regulatory agencies' requirements – On track to report topline data by the end of 2024, reinforcing Bylvay's expected position as first IBAT inhibitor to market in biliary atresia...